MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

George Evans had the opportunity of a lifetime as he stepped up to the mound to throw the first pitch at the Athletics game against the Houston Astros ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced ...

Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

Engaging in leisure-time moderate- to vigorous-intensity physical activity (MVPA) is associated with better overall survival for participants with a history of various cancers.

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.